If the IND is approved, and CX1739 is used in clinical trials for ADHD, corx could turn around nicely. To a lesser extent, a good SA outcome would also offer a path to profitability.
This company is toast though, if it can't get its compounds approved for chronic use. That has to happen soon. All the new compounds are meaningless if none of them can be brought to the clinic.
Market Data 
Markets 
AI
